PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26197437-4	2015	Fingolimod, an immune modulatory drug whose structure is similar to S1P, has been approved for treatment in multiple sclerosis (MS): fingolimod reduces the rate of MS relapses by preventing leukocyte egress from the lymph nodes.	Fingolimod Hydrochloride	0-10	membrane bound transcription factor peptidase, site 1	Homo sapiens	68-71	
26197437-4	2015	Fingolimod, an immune modulatory drug whose structure is similar to S1P, has been approved for treatment in multiple sclerosis (MS): fingolimod reduces the rate of MS relapses by preventing leukocyte egress from the lymph nodes.	Fingolimod Hydrochloride	133-143	membrane bound transcription factor peptidase, site 1	Homo sapiens	68-71	
24641481-9	2014	FTY720-P stimulated a higher level of beta-arrestin recruitment at S1P1Rs, 132% of the total recruited by S1P.	Fingolimod Hydrochloride	0-6	membrane bound transcription factor peptidase, site 1	Homo sapiens	67-70	
18638568-5	2008	We believe that the seminal event was the linking of the investigational drug, FTY720 (fingolimod), to S1P signaling.	Fingolimod Hydrochloride	79-85	membrane bound transcription factor peptidase, site 1	Homo sapiens	103-106	
18638568-5	2008	We believe that the seminal event was the linking of the investigational drug, FTY720 (fingolimod), to S1P signaling.	Fingolimod Hydrochloride	87-97	membrane bound transcription factor peptidase, site 1	Homo sapiens	103-106